Evidence map›Paper›PMID 30282635›Full record

ArticleThe Journal of biological chemistry2018

Mini-GAGR, an intranasally applied polysaccharide, activates the neuronal Nrf2-mediated antioxidant defense system.

Kelsey Murphy, Killian Llewellyn, Samuel Wakser, Josef Pontasch, Natasha Samanich, Matthew Flemer, Kenneth Hensley, Dong-Shik Kim, Joshua Park

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Reinforcing Nrf2 Signaling: Help in the Alzheimer's Disease Context.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Exploring the Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kelsey MurphyFrom the Departments of Neurosciences and.
Killian LlewellynFrom the Departments of Neurosciences and.
Samuel WakserFrom the Departments of Neurosciences and.
Josef PontaschFrom the Departments of Neurosciences and.
Natasha SamanichFrom the Departments of Neurosciences and.
Matthew FlemerFrom the Departments of Neurosciences and.
Kenneth HensleyPathology, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio 43614 and.
Dong-Shik Kimthe Department of Chemical Engineering, College of Engineering, University of Toledo, Toledo, Ohio 43607.
Joshua ParkFrom the Departments of Neurosciences and. Electronic address: joshua.park2@utoledo.edu.
Center for Neurosciences · USUniversity of Toledo · USNeurosciences Institute · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
A BBB-permeable neurotrophic polysaccharide, midi-GAGRR21AG053590 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI PARK, JOSHUA JIN-HYOUK · 2016 to 2017
$417k
NIA NIH HHS R21 AG053590NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

Oxidative stress triggers and exacerbates neurodegeneration in Alzheimer's disease (AD). Various antioxidants reduce oxidative stress, but these agents have little efficacy due to poor blood-brain barrier (BBB) permeability. Additionally, single-modal antioxidants are easily overwhelmed by global oxidative stress. Activating nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and its downstream antioxidant system are considered very effective for reducing global oxidative stress. Thus far, only a few BBB-permeable agents activate the Nrf2-dependent antioxidant system. Here, we discovered a BBB-bypassing Nrf2-activating polysaccharide that may attenuate AD pathogenesis. Mini-GAGR, a 0.7-kDa cleavage product of low-acyl gellan gum, increased the levels and activities of Nrf2-dependent antioxidant enzymes, decreased reactive oxygen species (ROS) under oxidative stress in mouse cortical neurons, and robustly protected mitochondria from oxidative insults. Moreover, mini-GAGR increased the nuclear localization and transcriptional activity of Nrf2 similarly to known Nrf2 activators. Mechanistically, mini-GAGR increased the dissociation of Nrf2 from its inhibitor, Kelch-like ECH-associated protein 1 (Keap1), and induced phosphorylation and nuclear translocation of Nrf2 in a protein kinase C (PKC)- and fibroblast growth factor receptor (FGFR1)-dependent manner. Finally, 20-day intranasal treatment of 3xTg-AD mice with 100 nmol of mini-GAGR increased nuclear p-Nrf2 and growth-associated protein 43 (GAP43) levels in hippocampal neurons, reduced p-tau and β-amyloid (Aβ) peptide-stained neurons, and improved memory. The BBB-bypassing Nrf2-activating polysaccharide reported here may be effective in reducing oxidative stress and neurodegeneration in AD.

Indexed as

Administration, IntranasalAlzheimer DiseaseAnimalsAntioxidantsBlood-Brain BarrierFemaleHumansMiceMice, Inbred BALB CNeuronsNF-E2-Related Factor 2Oxidative StressPhosphorylationPolysaccharides, BacterialReactive Oxygen SpeciesAntioxidantsgellan gumNF-E2-Related Factor 2Polysaccharides, BacterialReactive Oxygen SpeciesAlzheimer diseaseamyloidantioxidantantioxidant enzymesBBB-bypassing polysaccharidemini-GAGRneurodegenerationnuclear factor 2 (erythroid-derived 2-like factor) (NFE2L2) (Nrf2)oxidative stresspolysaccharidetau

Identifiers

PMID30282635
PMCPMC6254342
OpenAlexW2895177478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.